Wave Life Sciences, Inc. (WVE) stock
WVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/3046% below fair value
$2.84−0.03 (-1.05%)
Close on Nov 17, 2026Market cap $560.13MP/E –Yield –
Wave Life Sciences r&d expenses
Research and development expenses are spending on new products and technology.
Wave Life Sciences's R&D Expenses for the twelve months ending Sep 30, 2026 was $205.39M, up 17.6% year over year. For fiscal 2025 it was $182.78M, up 14.5% from the year before. Over ten years it grew 35.0% a year on average. The highest annual figure on record is $182.78M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $182.78M | +14.5% |
| FY2024 | Dec 31, 2024 | $159.68M | +22.8% |
| FY2023 | Dec 31, 2023 | $130.01M | +12.2% |
| FY2022 | Dec 31, 2022 | $115.86M | -4.9% |
| FY2021 | Dec 31, 2021 | $121.88M | -6.9% |
| FY2020 | Dec 31, 2020 | $130.94M | -25.4% |
| FY2019 | Dec 31, 2019 | $175.43M | +30.5% |
| FY2018 | Dec 31, 2018 | $134.43M | +69.5% |
| FY2017 | Dec 31, 2017 | $79.31M | +94.3% |
| FY2016 | Dec 31, 2016 | $40.82M | +350.7% |
| FY2015 | Dec 31, 2015 | $9.06M | +278.2% |
| FY2014 | Dec 31, 2014 | $2.40M | +24.7% |
| FY2013 | Dec 31, 2013 | $1.92M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $53.84M | +17.4% |
| Q2 FY2026 | Jun 30, 2026 | $51.29M | +18.0% |
| Q1 FY2026 | Mar 31, 2026 | $47.44M | +16.8% |
| Q4 FY2025 | Dec 31, 2025 | $52.81M | +18.3% |
| Q3 FY2025 | Sep 30, 2025 | $45.87M | +11.4% |
| Q2 FY2025 | Jun 30, 2025 | $43.47M | +7.6% |
| Q1 FY2025 | Mar 31, 2025 | $40.62M | +21.5% |
| Q4 FY2024 | Dec 31, 2024 | $44.65M | +31.0% |
| Q3 FY2024 | Sep 30, 2024 | $41.20M | +30.2% |
| Q2 FY2024 | Jun 30, 2024 | $40.39M | +21.2% |
| Q1 FY2024 | Mar 31, 2024 | $33.45M | +8.0% |
| Q4 FY2023 | Dec 31, 2023 | $34.07M | +9.6% |
| Q3 FY2023 | Sep 30, 2023 | $31.64M | +14.7% |
| Q2 FY2023 | Jun 30, 2023 | $33.31M | +12.0% |
| Q1 FY2023 | Mar 31, 2023 | $30.98M | +12.8% |
| Q4 FY2022 | Dec 31, 2022 | $31.08M | +20.6% |
| Q3 FY2022 | Sep 30, 2022 | $27.58M | -11.3% |
| Q2 FY2022 | Jun 30, 2022 | $29.73M | -6.0% |
| Q1 FY2022 | Mar 31, 2022 | $27.47M | -17.7% |
| Q4 FY2021 | Dec 31, 2021 | $25.76M | -14.2% |
| Q3 FY2021 | Sep 30, 2021 | $31.09M | +9.9% |
| Q2 FY2021 | Jun 30, 2021 | $31.64M | +0.5% |
| Q1 FY2021 | Mar 31, 2021 | $33.39M | -18.9% |
| Q4 FY2020 | Dec 31, 2020 | $30.03M | -38.9% |
| Q3 FY2020 | Sep 30, 2020 | $28.28M | -36.6% |
| Q2 FY2020 | Jun 30, 2020 | $31.48M | -24.3% |
| Q1 FY2020 | Mar 31, 2020 | $41.16M | +2.6% |
| Q4 FY2019 | Dec 31, 2019 | $49.13M | +23.4% |
| Q3 FY2019 | Sep 30, 2019 | $44.59M | +35.6% |
| Q2 FY2019 | Jun 30, 2019 | $41.61M | +27.8% |
| Q1 FY2019 | Mar 31, 2019 | $40.11M | +37.4% |
| Q4 FY2018 | Dec 31, 2018 | $39.81M | +56.9% |
| Q3 FY2018 | Sep 30, 2018 | $32.88M | +63.6% |
| Q2 FY2018 | Jun 30, 2018 | $32.55M | +70.4% |
| Q1 FY2018 | Mar 31, 2018 | $29.20M | +98.1% |
| Q4 FY2017 | Dec 31, 2017 | $25.37M | +81.3% |
| Q3 FY2017 | Sep 30, 2017 | $20.10M | – |
| Q2 FY2017 | Jun 30, 2017 | $19.10M | – |
| Q1 FY2017 | Mar 31, 2017 | $14.74M | – |
| Q4 FY2016 | Dec 31, 2016 | $14.00M | – |
See a number that looks wrong?